Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 336

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents

Steinman, Michael A., Bero, Lisa A., Chren, Mary-Margaret, Landefeld, C. Seth · 2006 · Annals of Internal Medicine

Abstract

BACKGROUND: Internal documents from the pharmaceutical industry provide a unique window for understanding the structure and methods of pharmaceutical promotion. Such documents have become available through litigation concerning the promotion of gabapentin (Neurontin, Pfizer, Inc., New York, New York) for off-label uses. PURPOSE: To describe how gabapentin was promoted, focusing on the use of medical education, research, and publication. DATA SOURCES: Court documents available to the public from United States ex. rel David Franklin vs. Pfizer, Inc., and Parke-Davis, Division of Warner-Lambert Company, mostly from 1994-1998. DATA EXTRACTION: All documents were reviewed by 1 author, with selected review by coauthors. Marketing strategies and tactics were identified by using an iterative process of review, discussion, and re-review of selected documents. DATA SYNTHESIS: The promotion of gabapentin was a comprehensive and multifaceted process. Advisory boards, consultants meetings, and accredited continuing medical education events organized by third-party vendors were used to deliver promotional messages. These tactics were augmented by the recruitment of local champions and engagement of thought leaders, who could be used to communicate favorable messages about gabapentin to their physician colleagues. Research and scholarship were also used for marketing by encouraging "key customers" to participate in research, using a large study to advance promotional themes and build market share, paying medical communication companies to develop and publish articles about gabapentin for the medical literature, and planning to suppress unfavorable study results. LIMITATIONS: Most available documents were submitted by the plaintiff and may not represent a complete picture of marketing practices. CONCLUSION: Activities traditionally considered independent of promotional intent, including continuing medical education and research, were extensively used to promote gabapentin. New strategies are needed to ensure a clear separation between scientific and commercial activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-145-4-200608150-00008

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Research works printed but not linked: 7

  1. 10.1001/jama.289.18.2418 · doi:10.1001/jama.289.18.2418
  2. 10.1056/NEJMp048322 · doi:10.1056/nejmp048322
  3. Pollack MH, 1997, CNS Spectrums, 55
  4. 10.1097/00007611-199907000-00001 · doi:10.1097/00007611-199907000-00001
  5. Gidal B, 1998, Consultant Pharmacist, 1, 62
  6. 10.18553/jmcp.1999.5.4.351 · doi:10.18553/jmcp.1999.5.4.351
  7. 1997, Fed Regist, 62, 64093

Cited by

See all 336

Metadata

Authors
Steinman, M. A., Bero, L. A., Chren, M.-M., & Landefeld, C. S.
Venue
Annals of Internal Medicine
Published
2006-08-15
Volume
145
Issue
4
Pages
284-293
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2162739163
Cited by
336
References
20
FWCI
3.20
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents. https://app.cochat.ai/papers/10.7326/0003-4819-145-4-200608150-00008
The paper
Steinman, M. A., Bero, L. A., Chren, M.-M., & Landefeld, C. S. (2006). Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-145-4-200608150-00008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.